Efficacy of a New Commercial Vaccine Against <i>Clostridioides difficile</i> and <i>Clostridium perfringens</i> Type A for Recurrent Swine Neonatal Diarrhea Under Field Conditions.

Animals (Basel) · 2025 · PMC12070884 · PMID 40362015

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a statistical trendno p-value reported

The percentage of piglets with diarrhea showed an LSM difference of 11.8% in the vaccine group, suggesting a statistical trend, although this difference was not statistically significant ( p = 0.051).

also in 1,573 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Efficacy of a New Commercial Vaccine Against &lt;i&gt;Clostridioides difficile&lt;/i&gt; and &lt;i&gt;Clostridium perfringens&lt;/i&gt; Type A for Recurrent Swine Neonatal Diarrhea Under Field Conditions.

The sentences

Efficacy of a New Commercial Vaccine Against <i>Clostridioides difficile</i> and <i>Clostridium perfringens</i> Type A for Recurrent Swine Neonatal Diarrhea Under Field Conditions.